Excited to share our new preprint—the main project of my postdoc in the Kaelin lab! Blocking HIF2 doesn’t just slow tumors—it can reverse cachexia and hypercalcemia in kidney cancer. In the OSRC-2 model, HIF2 inhibition restored weight, preserved fat/muscle, and rescued survival.

Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules!

Register to attend:

Join us for The Science of Childhood Cancer lecture series hosted by @StJudeResearch this Thursday, August 14 at 12 CT/1pm ET where Bill will be presenting The Von Hippel-Lindau tumor suppressor: insights into oxygen sensing, tumor immunity, and drugging the undruggable.

From the July issue: Requirement for Cyclin D1 Underlies Cell Autonomous HIF2-Dependence in Kidney Cancer https://t.co/ON6ZpUYjAr By @nitin_shirole89, @kaelin_lab, and colleagues at @DanaFarber

Congrats to @QinqinJiang88!! Go check out her and the team's work on ERVs and ccRCC https://t.co/0Qpox9xoQu

In 2023, the @FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, @kaelin_lab. Now, @DrChoueiri, director of @DanaFarber_GU, and team are working to expand its clinical use. https://t.co/WRNZ0ByKgb

Two of our wonderful technicians are off to medical school this summer! Mathew and Nora were great members of the lab, we are proud of them both!

We had a great time celebrating the group's many accomplishments!

We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to @nitin_shirole89 and the team!

New study just out from @kaelin_lab in @CD_AACR elucidating more about the dependence of #kidneycancer tumor cells on HIF2, implicating Cyclin D1 activity in resistance mechanisms to HIF2-targeted therapy

The latest collaboration led by the @kaelin_lab and #WuLab with @BraunMDPhD, #SteveCarr, #DerinKeskin @VanAllenLab @DanaFarber_GU @harvardmed @MIT @df_hcc in @CellCellPress: HIF-2, ERV, T cells, HLA, renal cell carcinoma, et al…. https://t.co/haEZPxCwgO

Study in @CellCellPress co-led by @DanaFarber’s William Kaelin, MD, and Catherine Wu, MD, suggests the immune system can mount an attack on cancer cells that, due to cancer-driving mutations, present fragments of endogenous retroviral proteins on their surface. ➡️

All spearheaded by the very talented @Qinqin32734657, @BraunMDPhD, Karl Clauser (@BroadProteomics)!

We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy https://t.co/0Qpox9xWG2

It’s Day 2 at @SABCSSanAntonio! Presentations by our @DFCI_BreastOnc faculty include olaparib for BRCA+ breast cancer, and #weightloss intervention. Don't miss the Keynote by Nobel laureate William Kaelin (@kaelin_lab). See our full #SABCS24 schedule: https://t.co/TN20nKGu7t

Another great year coming to a close! Happy Holidays to everyone!

(Re)emerging Principles for Controlling Cancer with Drugs: William Kaelin will address this topic in a Keynote Address at #SABCS24 (December 10-13). Learn more: https://t.co/7CkZPvQF3G @kaelin_lab

Big shoutout to @LAStransky @gaowh75 and Laura Schmidt for leading the team!

Check out the group’s recent collaborative project to establish a mouse model of Vhl-deficient clear cell kidney cancer! Great work everyone! https://t.co/jLH2oate99 @VanAllenLab @theNCI and many others!